ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
ABIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.00%104.101.1%$1332.57m
GILDGilead Sciences, Inc.
0.00%72.440.9%$675.30m
AMGNAmgen Inc.
0.00%170.001.1%$499.55m
BIIBBiogen Inc.
1.02%317.161.2%$472.85m
REGNRegeneron Pharmaceuticals, Inc.
0.00%391.592.7%$363.74m
ALXNAlexion Pharmaceuticals, Inc.
0.00%110.871.9%$288.55m
VRTXVertex Pharmaceuticals Incorporated
0.00%147.411.9%$237.28m
INCYIncyte Corporation
0.00%105.472.5%$187.59m
ALNYAlnylam Pharmaceuticals, Inc
0.00%127.5110.6%$184.43m
ILMNIllumina, Inc.
0.00%209.023.5%$165.18m
NKTRNektar Therapeutics
0.00%44.996.1%$146.11m
JUNOJuno Therapeutics, Inc.
0.00%58.6413.5%$138.44m
BMRNBioMarin Pharmaceutical Inc.
0.00%82.884.4%$117.68m
SRPTSarepta Therapeutics, Inc.
0.00%56.1116.8%$117.17m
BLUEBluebird Bio, Inc.
0.00%163.2017.2%$116.94m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.